Chang-hong Li
Zi-rui Lü3
Zhen-da Zhao
Hui-jie Leng
Yan Niu
Mo-pei Wang
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
- 1Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China
- 2Osteoporosis and Bone Metabolic Diseases Center, Peking University Third Hospital, Beijing, China
- 3Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, China
- 4Department of Orthopaedics, Peking University Third Hospital, Beijing, China
- 5Beijing Key Laboratory of Spinal Disease Research, Beijing, China
- 6Department of Tumor Chemotherapy and Radiation Sickness, Peking University Third Hospital, Beijing, China
A Corrigendum on
Nitazoxanide, an antiprotozoal drug, reduces bone loss in ovariectomized mice by inhibition of RANKL-induced osteoclastogenesis
by Li C-h, Lü Z-r, Zhao Z-d, Wang X-y, Leng H-j, Niu Y and Wang M-p (2021). Front. Pharmacol. 12:781640. doi: 10.3389/fphar.2021.781640
In the published article, there was an error in the Funding statement. The original statement read: “This work was supported by National Natural Science Foundation of China (No. 81501387, No. 12172011, No. 11872076), Bethune Osteoporosis Foundation Project (G-X-2020-1107-02) and Youth Backbone Incubation Fund of Peking University Third Hospital (BYSYFY2021027).” This statement should be corrected as follows:
Funding
This work was supported by Scientific Research Foundation of Returned Scholars of Peking University Third Hospital (LXHG2018003), National Natural Science Foundation of China (Nos 81501387, 12172011, and 11872076), Bethune Osteoporosis Foundation Project (G-X-2020-1107-02), and Youth Backbone Incubation Fund of Peking University Third Hospital (BYSYFY2021027).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: nitazoxanide, stat3, osteoclastogenesis, Nfatc1, osteoporosis
Citation: Li C-h, Lü Z-r, Zhao Z-d, Wang X-y, Leng H-j, Niu Y and Wang M-p (2023) Corrigendum: Nitazoxanide, an antiprotozoal drug, reduces bone loss in ovariectomized mice by inhibition of RANKL-induced osteoclastogenesis. Front. Pharmacol. 14:1247393. doi: 10.3389/fphar.2023.1247393
Received: 26 June 2023; Accepted: 04 July 2023;
Published: 26 July 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Li, Lü, Zhao, Wang, Leng, Niu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hui-jie Leng, bGVuZ2hqQGJqbXUuZWR1LmNu; Yan Niu, eWFubml1QGJqbXUuZWR1LmNu; Mo-pei Wang, d2FuZ21vcGVpQDEyNi5jb20=